SLC22A4 and hemorrhagic stroke: Our study provides the first comprehensive exploration of targets involved in SAH and ICH using eQTL data to provide genetic support for hemorrhagic stroke drug development and is the first to report that TNFSF12, SLC22A4, and SPARC have preventive effects on IA, SAH, and ICH.